Practice parameter for the use of red blood cell transfusions

Developed by the Red Blood Cell Administration Practice Guideline Development Task Force of the College of American Pathologists

Toby L. Simon, Dale C. Alverson, James AuBuchon, Barbara J. Barrett, E. Shannon Cooper, Phillip J. DeChristopher, Guy C. Glenn, Steven A. Gould, Chantal R. Harrison, John D. Milam, Kenneth J. Moise, Francis Robert Rodwig, Laurence A. Sherman, Ira A. Shulman, Linda Stehling

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

A practice parameter has been developed to assist physicians in the therapeutic use of red blood cell transfusions. The developers of this parameter used the best available information from the medical literature, as well as clinical experience and the extensive reality testing required by the College of American Pathologists for approval. In acute anemia, a fall in hemoglobin values below 6 g/dL or a rapid blood volume loss of more than 30% to 40% requires red blood cell transfusions in most patients. However, tissue oxygenation provides a better indication of physiologic need in situations where invasive monitoring provides this information. When these data are not available, heart rate and blood pressure measurements and the nature of bleeding (active, controlled, uncontrolled) supplement the hemoglobin value in guiding the transfusion decision. In sickle cell disease and thalassemias, red blood cells are transfused to prevent acute or chronic complications. Red blood cell transfusions are used in chronic anemias unresponsive to pharmacologic agents based on the patient's symptoms. Guidelines must be altered for neonates who require an increase in hematocrit to above 0.30 to 0.35 when respiratory distress is present. Indications for red blood cell transfusion for the pregnant or postpartum patient are similar to those for the nonpregnant patient. Risks of transfusion, particularly transmissible disease and incompatibility, remain but have been reduced. Thus, red blood cell transfusion continues to be a powerful therapeutic tool when used judiciously and carries less risk than in the recent past.

Original languageEnglish (US)
Pages (from-to)130-138
Number of pages9
JournalArchives of Pathology and Laboratory Medicine
Volume122
Issue number2
StatePublished - 1998
Externally publishedYes

Fingerprint

Erythrocyte Transfusion
Advisory Committees
Practice Guidelines
Erythrocytes
Anemia
Hemoglobins
Reality Testing
Thalassemia
Sickle Cell Anemia
Therapeutic Uses
Blood Volume
Hematocrit
Postpartum Period
Heart Rate
Pathologists
Newborn Infant
Guidelines
Hemorrhage
Blood Pressure
Physicians

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Practice parameter for the use of red blood cell transfusions : Developed by the Red Blood Cell Administration Practice Guideline Development Task Force of the College of American Pathologists. / Simon, Toby L.; Alverson, Dale C.; AuBuchon, James; Barrett, Barbara J.; Cooper, E. Shannon; DeChristopher, Phillip J.; Glenn, Guy C.; Gould, Steven A.; Harrison, Chantal R.; Milam, John D.; Moise, Kenneth J.; Rodwig, Francis Robert; Sherman, Laurence A.; Shulman, Ira A.; Stehling, Linda.

In: Archives of Pathology and Laboratory Medicine, Vol. 122, No. 2, 1998, p. 130-138.

Research output: Contribution to journalArticle

Simon, TL, Alverson, DC, AuBuchon, J, Barrett, BJ, Cooper, ES, DeChristopher, PJ, Glenn, GC, Gould, SA, Harrison, CR, Milam, JD, Moise, KJ, Rodwig, FR, Sherman, LA, Shulman, IA & Stehling, L 1998, 'Practice parameter for the use of red blood cell transfusions: Developed by the Red Blood Cell Administration Practice Guideline Development Task Force of the College of American Pathologists', Archives of Pathology and Laboratory Medicine, vol. 122, no. 2, pp. 130-138.
Simon, Toby L. ; Alverson, Dale C. ; AuBuchon, James ; Barrett, Barbara J. ; Cooper, E. Shannon ; DeChristopher, Phillip J. ; Glenn, Guy C. ; Gould, Steven A. ; Harrison, Chantal R. ; Milam, John D. ; Moise, Kenneth J. ; Rodwig, Francis Robert ; Sherman, Laurence A. ; Shulman, Ira A. ; Stehling, Linda. / Practice parameter for the use of red blood cell transfusions : Developed by the Red Blood Cell Administration Practice Guideline Development Task Force of the College of American Pathologists. In: Archives of Pathology and Laboratory Medicine. 1998 ; Vol. 122, No. 2. pp. 130-138.
@article{f57cd90c050540948cfb057c197295d7,
title = "Practice parameter for the use of red blood cell transfusions: Developed by the Red Blood Cell Administration Practice Guideline Development Task Force of the College of American Pathologists",
abstract = "A practice parameter has been developed to assist physicians in the therapeutic use of red blood cell transfusions. The developers of this parameter used the best available information from the medical literature, as well as clinical experience and the extensive reality testing required by the College of American Pathologists for approval. In acute anemia, a fall in hemoglobin values below 6 g/dL or a rapid blood volume loss of more than 30{\%} to 40{\%} requires red blood cell transfusions in most patients. However, tissue oxygenation provides a better indication of physiologic need in situations where invasive monitoring provides this information. When these data are not available, heart rate and blood pressure measurements and the nature of bleeding (active, controlled, uncontrolled) supplement the hemoglobin value in guiding the transfusion decision. In sickle cell disease and thalassemias, red blood cells are transfused to prevent acute or chronic complications. Red blood cell transfusions are used in chronic anemias unresponsive to pharmacologic agents based on the patient's symptoms. Guidelines must be altered for neonates who require an increase in hematocrit to above 0.30 to 0.35 when respiratory distress is present. Indications for red blood cell transfusion for the pregnant or postpartum patient are similar to those for the nonpregnant patient. Risks of transfusion, particularly transmissible disease and incompatibility, remain but have been reduced. Thus, red blood cell transfusion continues to be a powerful therapeutic tool when used judiciously and carries less risk than in the recent past.",
author = "Simon, {Toby L.} and Alverson, {Dale C.} and James AuBuchon and Barrett, {Barbara J.} and Cooper, {E. Shannon} and DeChristopher, {Phillip J.} and Glenn, {Guy C.} and Gould, {Steven A.} and Harrison, {Chantal R.} and Milam, {John D.} and Moise, {Kenneth J.} and Rodwig, {Francis Robert} and Sherman, {Laurence A.} and Shulman, {Ira A.} and Linda Stehling",
year = "1998",
language = "English (US)",
volume = "122",
pages = "130--138",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "2",

}

TY - JOUR

T1 - Practice parameter for the use of red blood cell transfusions

T2 - Developed by the Red Blood Cell Administration Practice Guideline Development Task Force of the College of American Pathologists

AU - Simon, Toby L.

AU - Alverson, Dale C.

AU - AuBuchon, James

AU - Barrett, Barbara J.

AU - Cooper, E. Shannon

AU - DeChristopher, Phillip J.

AU - Glenn, Guy C.

AU - Gould, Steven A.

AU - Harrison, Chantal R.

AU - Milam, John D.

AU - Moise, Kenneth J.

AU - Rodwig, Francis Robert

AU - Sherman, Laurence A.

AU - Shulman, Ira A.

AU - Stehling, Linda

PY - 1998

Y1 - 1998

N2 - A practice parameter has been developed to assist physicians in the therapeutic use of red blood cell transfusions. The developers of this parameter used the best available information from the medical literature, as well as clinical experience and the extensive reality testing required by the College of American Pathologists for approval. In acute anemia, a fall in hemoglobin values below 6 g/dL or a rapid blood volume loss of more than 30% to 40% requires red blood cell transfusions in most patients. However, tissue oxygenation provides a better indication of physiologic need in situations where invasive monitoring provides this information. When these data are not available, heart rate and blood pressure measurements and the nature of bleeding (active, controlled, uncontrolled) supplement the hemoglobin value in guiding the transfusion decision. In sickle cell disease and thalassemias, red blood cells are transfused to prevent acute or chronic complications. Red blood cell transfusions are used in chronic anemias unresponsive to pharmacologic agents based on the patient's symptoms. Guidelines must be altered for neonates who require an increase in hematocrit to above 0.30 to 0.35 when respiratory distress is present. Indications for red blood cell transfusion for the pregnant or postpartum patient are similar to those for the nonpregnant patient. Risks of transfusion, particularly transmissible disease and incompatibility, remain but have been reduced. Thus, red blood cell transfusion continues to be a powerful therapeutic tool when used judiciously and carries less risk than in the recent past.

AB - A practice parameter has been developed to assist physicians in the therapeutic use of red blood cell transfusions. The developers of this parameter used the best available information from the medical literature, as well as clinical experience and the extensive reality testing required by the College of American Pathologists for approval. In acute anemia, a fall in hemoglobin values below 6 g/dL or a rapid blood volume loss of more than 30% to 40% requires red blood cell transfusions in most patients. However, tissue oxygenation provides a better indication of physiologic need in situations where invasive monitoring provides this information. When these data are not available, heart rate and blood pressure measurements and the nature of bleeding (active, controlled, uncontrolled) supplement the hemoglobin value in guiding the transfusion decision. In sickle cell disease and thalassemias, red blood cells are transfused to prevent acute or chronic complications. Red blood cell transfusions are used in chronic anemias unresponsive to pharmacologic agents based on the patient's symptoms. Guidelines must be altered for neonates who require an increase in hematocrit to above 0.30 to 0.35 when respiratory distress is present. Indications for red blood cell transfusion for the pregnant or postpartum patient are similar to those for the nonpregnant patient. Risks of transfusion, particularly transmissible disease and incompatibility, remain but have been reduced. Thus, red blood cell transfusion continues to be a powerful therapeutic tool when used judiciously and carries less risk than in the recent past.

UR - http://www.scopus.com/inward/record.url?scp=0031930072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031930072&partnerID=8YFLogxK

M3 - Article

VL - 122

SP - 130

EP - 138

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 2

ER -